サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1575043

トキソプラズマ症治療市場：タイプ別、投与経路別、薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Toxoplasmosis Treatment Market, By Type, By Route of Administration, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
トキソプラズマ症治療市場：タイプ別、投与経路別、薬剤クラス別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

トキソプラズマ症治療の市場規模は、2023年に31億9,032万米ドルとなり、2024年から2032年にかけてCAGR6.60％で拡大しました。

この市場を牽引しているのは、疾患に対する認識の高まり、脆弱な集団における有病率の上昇、薬剤開発の進歩です。さらに、より効果的で的を絞った治療法の研究が進んでいることも、市場の将来的な展望を形成すると予想されます。全体として、トキソプラズマ症治療市場は、特に罹患率の高い地域において、公衆衛生において重要な役割を果たしています。

トキソプラズマ症治療市場 - 市場ダイナミクス

胎児の発育に対する潜在的合併症への理解の高まり

妊娠中のトキソプラズマ症による潜在的合併症に対する認識の高まりは、トキソプラズマ症治療市場の重要な促進要因となっています。トキソプラズマ症は、寄生虫トキソプラズマ・ゴンディによって引き起こされ、神経学的問題や発達遅延など、胎児に深刻な問題を引き起こす可能性があります。米国疾病予防管理センター（CDC）によると、米国では年間約400人から4,000人の乳児が先天性トキソプラズマ症で生まれており、10％から15％が深刻な健康合併症に直面する可能性があるといいます。このような理解が深まるにつれ、ヘルスケア提供者は妊婦に定期的なスクリーニングを推奨するようになり、検査と効果的な治療の両方に対する需要が高まっています。その結果、製薬会社は革新的な治療法や予防法の開発にますます意欲的になり、このような差し迫った健康問題に対応した市場拡大を促進しています。

トキソプラズマ症治療市場 - 主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）に約6.60%のCAGRで毎年成長すると推定されます。

タイプ別セグメンテーションでは、先天性トキソプラズマ症が2023年に最大の市場シェアを示すと予測されていました。

投与経路のセグメンテーションに基づくと、2023年には経口剤が主要タイプでした。

薬剤クラス別では、2023年にピリメタミンが主要タイプでした。

地域別では、北米が2023年の収益でトップとなりました。

トキソプラズマ症治療市場 - セグメンテーション分析：

世界のトキソプラズマ症治療市場は、タイプ、投与経路、薬剤クラス別、流通チャネル、地域に基づいてセグメント化されます。

市場は、タイプ別に2つに分類されます：後天性トキソプラズマ症と先天性トキソプラズマ症です。先天性トキソプラズマ症は最も重要なセグメントです。先天性トキソプラズマ症が最も重要なセグメントである理由は、新生児に対する重大な健康影響と、早期発見と介入に関する医療従事者の意識の高まりにあります。先天性トキソプラズマ症は重篤な神経学的合併症や眼合併症を引き起こす可能性があり、効果的な治療が不可欠です。妊娠中の母体感染率の増加は、標的治療と予防措置の必要性をさらに強調しています。その結果、この脆弱な集団に対する治療選択肢の改善に焦点を当てた研究開発に多額の投資が行われています。

市場は薬剤クラス別に5つのカテゴリーに分類されます：ピリメタミン、スピラマイシン、ロイコボリン、スルファジアジン、葉酸、その他です。ピリメタミンは最も重要な薬剤クラス別です。ピリメタミンは、急性および慢性のトキソプラズマ症、特に免疫不全患者や重篤な症状を有する患者に対する一次治療薬として有効であることから注目されています。ピリメタミンは寄生虫量を減少させる能力があり、併用療法での使用も確立されていることから、臨床現場での重要性が高まっています。さらに、投与量を最適化し副作用を最小限に抑えるための継続的な調査により、治療プロトコールにおけるピリメタミンの優位性が強化され、トキソプラズマ症治療の要となっています。

トキソプラズマ症治療市場 - 地理的洞察

トキソプラズマ症治療市場で最大の地域は北米です。この地域は、気候やペット飼育などの要因により、症例数が多いです。また、病気に対する認識の高まりやヘルスケアシステムの充実も市場を後押ししています。多くの企業が、患者を救うための新しい治療法や薬剤を開発しています。

この地域の研究開発は活発で、より効果的な選択肢を生み出しています。ヘルスケアプロバイダーと製薬会社のパートナーシップは、治療の有効性を高めています。全体として、北米はトキソプラズマ症治療市場の成長において重要な役割を果たしています。

トキソプラズマ症治療市場 - 競合情勢：

トキソプラズマ症治療市場の競合情勢は、Roche、Sanofi、Pfizerなどの大手製薬会社と革新的なバイオテクノロジー企業で占められています。現在の治療法には、主にピリメタミンとスルファジアジンまたはクリンダマイシンの併用がありますが、薬剤耐性に対処し有効性を向上させるための新規治療法の研究開発に重点が置かれています。地理的な成長としては、北米と欧州が顕著で、これは認知度の向上とヘルスケアへのアクセス向上に牽引されたもので、新興市場にも新たな機会がもたらされています。

学術機関との共同研究や合弁事業が研究開発能力を高める一方で、規制当局の承認プロセスは依然として重要です。市場の動向は個別化医療と先端治療薬に向かい、各社は製品の差別化と競争力のある価格設定に重点を置いた戦略を採用するようになっています。状況はダイナミックで、技術革新と進化する課題を乗り切る必要性を特徴としています。

目次

第1章 トキソプラズマ症治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 トキソプラズマ症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 トキソプラズマ症治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 トキソプラズマ症治療市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 トキソプラズマ症治療市場情勢

  • トキソプラズマ症治療市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 トキソプラズマ症治療市場 - タイプ別

  • 概要
    • セグメントシェア分析：タイプ別
    • 後天性トキソプラズマ症
    • 先天性トキソプラズマ症

第8章 トキソプラズマ症治療市場 - 投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 非経口
    • 経口

第9章 トキソプラズマ症治療市場 - 薬剤クラス別

  • 概要
    • セグメントシェア分析：薬剤クラス別
    • ピリメタミン
    • スピラマイシン
    • ロイコボリン
    • スルファジアジン
    • 葉酸
    • その他

第10章 トキソプラズマ症治療市場 - 流通チャネル別

  • 概要
    • セグメントシェア分析：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第11章 トキソプラズマ症治療市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析 - トキソプラズマ症治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Roche
    • Sanofi
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Bristol-Myers Squibb
    • AbbVie
    • Merck & Co.
    • Teva Pharmaceutical Industries
    • AstraZeneca
    • Gilead Sciences
    • Eisai Co., Ltd.
    • Lundbeck
    • Boehringer Ingelheim
    • Hoffmann - La Roche
    • Amgen

第13章 アナリストの全方位展望

目次
Product Code: ANV4045

REPORT HIGHLIGHT

The Toxoplasmosis Treatment Market size was valued at USD 3,190.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The toxoplasmosis treatment market encompasses a range of pharmaceutical products and therapies to manage infections caused by the parasite Toxoplasma gondii. This condition primarily affects immunocompromised individuals, pregnant women, and those with weakened immune systems, making effective treatment critical. Key medications include pyrimethamine, sulfadiazine, and clindamycin, often used in combination to enhance efficacy.

The market is driven by rising awareness of the disease, increasing prevalence in vulnerable populations, and advancements in drug development. Additionally, ongoing research into more effective and targeted therapies is expected to shape the future landscape of the market. Overall, the toxoplasmosis treatment market plays a vital role in public health, particularly in regions with high incidence rates.

Toxoplasmosis Treatment Market- Market Dynamics

Increased understanding of potential complications for fetal development.

The increasing awareness of the potential complications from toxoplasmosis during pregnancy has become a significant driver for the toxoplasmosis treatment market. Toxoplasmosis, caused by the parasite Toxoplasma gondii, can lead to severe issues in unborn children, including neurological problems and developmental delays. According to the Centers for Disease Control and Prevention (CDC), around 400 to 4,000 infants are born annually in the U.S. with congenital toxoplasmosis, with 10% to 15% potentially facing serious health complications. This growing understanding prompts healthcare providers to recommend routine screening for pregnant women, thereby elevating the demand for both testing and effective treatments. As a result, pharmaceutical companies are increasingly motivated to develop innovative therapies and preventive measures, fostering market expansion in response to these pressing health concerns.

Toxoplasmosis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Type segmentation, Congenital Toxoplasmosis was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, oral was the leading type in 2023

Based on Drug Class segmentation, Pyrimethamine was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Toxoplasmosis Treatment Market- Segmentation Analysis:

The Global Toxoplasmosis Treatment Market is segmented based on Type, Route of Administration, Drug Class, Distribution Channel, and Region.

The market is divided into two categories based on Type: Acquired Toxoplasmosis and congenital Toxoplasmosis. Congenital Toxoplasmosis is the most significant segment. This prominence arises from the critical health implications for newborns and the heightened awareness among healthcare providers regarding early detection and intervention. Congenital infections can lead to severe neurological and ocular complications, making effective treatment vital. The increasing incidence of maternal infection during pregnancy further emphasizes the need for targeted therapies and preventative measures. As a result, there is substantial investment in research and development focused on improving treatment options for this vulnerable population.

The market is divided into five categories based on Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others. Pyrimethamine is the most significant drug class. Its prominence stems from its effectiveness as a primary treatment for both acute and chronic toxoplasmosis, particularly in immunocompromised patients and those with severe symptoms. Pyrimethamine's ability to reduce the parasite load and its established use in combination therapies enhance its importance in clinical practice. Additionally, the ongoing research into optimizing its dosage and minimizing side effects continues to reinforce its dominant position in treatment protocols, making it a cornerstone in managing Toxoplasmosis.

Toxoplasmosis Treatment Market- Geographical Insights

The largest region in the toxoplasmosis treatment market is North America. This area has a high number of cases due to factors like climate and pet ownership. The growing awareness of the disease and better healthcare systems also boost the market. Many companies are developing new treatments and drugs to help patients.

Research and development in this region are strong, leading to more effective options. Partnerships between healthcare providers and pharmaceutical companies enhance treatment availability. Overall, North America plays a key role in the growth of the toxoplasmosis treatment market.

Toxoplasmosis Treatment Market- Competitive Landscape:

The Toxoplasmosis treatment market features a competitive landscape dominated by major pharmaceutical companies like Roche, Sanofi, and Pfizer, alongside innovative biotech firms. Current treatment options primarily include pyrimethamine combined with sulfadiazine or clindamycin, there is a growing emphasis on research and development for novel therapies to address drug resistance and improve efficacy. Geographic growth is notable in North America and Europe, driven by increased awareness and healthcare access, with emerging markets presenting additional opportunities.

Collaborative efforts with academic institutions and joint ventures enhance R&D capabilities, while regulatory approval processes remain crucial. The market trends towards personalized medicine and advanced therapeutics, prompting companies to adopt strategies focusing on product differentiation and competitive pricing. The landscape is dynamic, characterized by innovation and a need to navigate evolving challenges.

Recent Developments:

In April 2023, Computational screening of FDA-approved drugs aims to identify potential inhibitors of Toxoplasma gondii proteins like TgDHFR, TgPRS, and TgCDPK1 through molecular docking, stability assessments, and ADMET analysis, followed by in vitro validation of promising candidates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TOXOPLASMOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Roche
  • Sanofi
  • Pfizer
  • Novartis
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • AbbVie
  • Merck & Co.
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Gilead Sciences
  • Eisai Co., Ltd.
  • Lundbeck
  • Boehringer Ingelheim
  • Hoffmann-La Roche
  • Amgen

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acquired Toxoplasmosis
  • Congenital Toxoplasmosis

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Pyrimethamine
  • Spiramycin
  • Leucovorin
  • Sulfadiazine
  • Folic Acid
  • Other

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Toxoplasmosis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Toxoplasmosis Treatment Market Snippet by Type
    • 2.1.2. Toxoplasmosis Treatment Market Snippet by Route of Administration
    • 2.1.3. Toxoplasmosis Treatment Market Snippet by Drug Class
    • 2.1.4. Toxoplasmosis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Toxoplasmosis Treatment Market Snippet by Country
    • 2.1.6. Toxoplasmosis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Toxoplasmosis Treatment Key Market Trends

  • 3.1. Toxoplasmosis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Toxoplasmosis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Toxoplasmosis Treatment Market Opportunities
  • 3.4. Toxoplasmosis Treatment Market Future Trends

4. Toxoplasmosis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Toxoplasmosis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Toxoplasmosis Treatment Market Landscape

  • 6.1. Toxoplasmosis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Toxoplasmosis Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Acquired Toxoplasmosis
    • 7.1.3. Congenital Toxoplasmosis

8. Toxoplasmosis Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Toxoplasmosis Treatment Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 9.1.2. Pyrimethamine
    • 9.1.3. Spiramycin
    • 9.1.4. Leucovorin
    • 9.1.5. Sulfadiazine
    • 9.1.6. Folic Acid
    • 9.1.7. Other

10. Toxoplasmosis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Toxoplasmosis Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Toxoplasmosis Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Toxoplasmosis Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Toxoplasmosis Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Toxoplasmosis Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Toxoplasmosis Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Toxoplasmosis Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Roche
    • 12.2.2. Sanofi
    • 12.2.3. Pfizer
    • 12.2.4. Novartis
    • 12.2.5. GlaxoSmithKline
    • 12.2.6. Bristol-Myers Squibb
    • 12.2.7. AbbVie
    • 12.2.8. Merck & Co.
    • 12.2.9. Teva Pharmaceutical Industries
    • 12.2.10. AstraZeneca
    • 12.2.11. Gilead Sciences
    • 12.2.12. Eisai Co., Ltd.
    • 12.2.13. Lundbeck
    • 12.2.14. Boehringer Ingelheim
    • 12.2.15. Hoffmann-La Roche
    • 12.2.16. Amgen

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us